Sabby Management’s Quoin Pharmaceuticals QNRX Stock Holding History

Sabby Management’s Portfolio QNRX Stock Details QNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2	Closed	-$124K	–	103
2019 Q2	$124K	Hold	2	–	–	0.16%	65
2019 Q1	$214K	Buy	+2	New	+$359K	0.1%	48
2018 Q4	–	Sell	-1	Closed	-$423K	–	87
2018 Q3	$412K	Hold	1	–	–	0.05%	78
2018 Q2	$798K	Sell	1 -1	-50%	-$731K	0.12%	69
2018 Q1	$1.56M	Buy	+2	New	+$1.65M	0.19%	46
2017 Q1	–	Sell	-1	Closed	-$177K	–	299
2016 Q4	$177K	Hold	1	–	–	0.01%	249
2016 Q3	$264K	Buy	+1	New	+$494K	0.01%	260

Other funds holding QNRX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sabby Management's QNRX Position: Q3 2019 in Review

Sabby Management sold out of Quoin Pharmaceuticals (QNRX) in Q3 2019, closing a stake of 2 shares — an estimated $124K sold.

Sabby Management first reported a position in QNRX in Q3 2016 and held it in 7 quarters. The position peaked at $1.56M in Q1 2018. 3 funds tracked by Wall St. Rank hold QNRX as of Q3 2019.

Sabby Management reported no remaining Quoin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Sabby Management sold 2 Quoin Pharmaceuticals shares in Q3 2019, an estimated $124K.
Sabby Management first reported a position in Quoin Pharmaceuticals in Q3 2016 and held it in 7 quarters.
Sabby Management's Quoin Pharmaceuticals position peaked at $1.56M in Q1 2018.
3 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q3 2019.

Based on Sabby Management's 13F filing for Q3 2019, filed 15 Nov 2019.